- U.S. government officials are putting an early end to a study testing an Eli Lilly's (NYSE:LLY) antibody drug for hospitalized patients with COVID-19 as it doesn’t seem to be helping them.
- Independent monitors had paused enrollment two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases found no safety problem but a low chance that the drug would prove helpful for hospitalized patients.
- President Donald Trump received a similar experimental, two-antibody drug from Regeneron Pharmaceuticals (NASDAQ:REGN).
- However, the government and Company will continue separate studies testing antibody drug in mild to moderately ill patients.
- Lilly and Regeneron have asked the FDA to grant emergency use authorization for their drugs for COVID-19 while late-stage studies continue
- Previously: Eli Lilly's Covid-19 antibody trial paused over safety concerns (Oct. 13)
- https://seekingalpha.com/news/3626170-lilly-ends-covidminus-19-antibody-trial-after-lack-of-improvement
Tuesday, October 27, 2020
Lilly ends COVID-19 antibody trial after lack of improvement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.